Home
Journal Information
About
Aims and Scope
Editorial Board
Editor in Chief
Open Access
Editorial Office
Editorial Policies
Journal Issues
Current Issue
In Press
All Issues
Contact Us
Create Account
Login
Please don't use dangerous characters
Title
Author
Abstract
Keywords
First Name
Last Name
Search
ISSN
:
2008-5117
eISSN
:
2008-6830
Submit Your Paper
Instructions for Authors
Instructions for Reviewers
Editor in Chief
Editorial Board
Editorial Policies
English Editing Service
Indexing and Abstracting
Archive
Platinum Open Access
This Platinum Open Access journal publishes articles totally free of charge for the authors and provides unrestricted access to the published content through its website and open access repositories such as PubMed Central. All related costs for processing of the manuscripts are sponsored by Tabriz University of Medical Sciences.
Indexing Info
Collaborator of
J Cardiovasc Thorac Res
. 2020;12(1): 20-26. doi:
10.34172/jcvtr.2020.04
PMID:
32211134
PMCID:
PMC7080335
Original Article
Agreement between Framingham, IraPEN and non-laboratory WHO-EMR risk score calculators for cardiovascular risk prediction in a large Iranian population
Mohsen Mirzaei
1
, Masoud Mirzaei
1
*
Cited by CrossRef: 3
1- Hasandokht T, Maroufizadeh S, Joukar F, Salari A, Mansour-Ghanaei F. Ten-Year Cardiovascular Disease Risk Evaluation in PERSIAN Guilan Cohort Study: A Cross-Sectional Study.
J Occup Health Epidemiol
. 2023;12(2):78
[Crossref]
2- Rezaei F, Seif M, Gandomkar A, Fattahi M, Hasanzadeh J. Agreement between laboratory-based and non-laboratory-based Framingham risk score in Southern Iran.
Sci Rep
. 2021;11(1)
[Crossref]
3- Dehghan A, Ahmadnia Motlagh S, Khezri R, Rezaei F, Aune D. A comparison of laboratory-based and office-based Framingham risk scores to predict 10-year risk of cardiovascular diseases: a population-based study.
J Transl Med
. 2023;21(1)
[Crossref]
4- Saki N, Babaahmadi-Rezaei H, Rahimi Z, Raeisizadeh M, Jorfi F, Seif F, Cheraghian B, Ghaderi-Zefrehi H, Rezaei M. Impact of modifiable risk factors on prediction of 10-year cardiovascular disease utilizing framingham risk score in Southwest Iran.
BMC Cardiovasc Disord
. 2023;23(1)
[Crossref]
5- Yang X, Huang K, Yang D, Zhao W, Zhou X. Biomedical Big Data Technologies, Applications, and Challenges for Precision Medicine: A Review.
Global Challenges
. 2024;8(1)
[Crossref]
6- Agyekum F, Akumiah F, Nguah S, Appiah L, Ganatra K, Adu-Boakye Y, Folson A, Ayetey H, Owusu I. Atherosclerotic cardiovascular disease risk among Ghanaians: A comparison of the risk assessment tools..
American Journal of Preventive Cardiology
. 2024;18:100670
[Crossref]
7- Faramarzi E, Somi M, Ostadrahimi A, Molani-Gol R, Khamnian Z, Ghaffari S, Amiri B. Risk estimation of cardiovascular diseases using the World Health Organization/International Society of Hypertension risk prediction charts in the Azar cohort population: Cross-sectional study.
J Cardiovasc Thorac Res
. 2024;16(2):88
[Crossref]
8- Thagizadeh A, Ghahramanian A, Zamanzadeh V, Aslanabadi N, Onyeka T, Ramazanzadeh N. Illness perception and cardiovascular risk factors in patients with myocardial infarction undergoing percutaneous coronary intervention in Iran.
BMC Cardiovasc Disord
. 2022;22(1)
[Crossref]
9- Momayyezi M, Sefidkar R, Fallahzadeh H. Agreement between ten-years cardiovascular disease risk assessment tools: An application to Iranian population in Shahedieh Cohort Study.
Heliyon
. 2023;9(10):e20396
[Crossref]